CDMO - September 28, 2023
NorthX Biologics inaugurates Innovation Hub
NorthX Biologics has announced the official inauguration of its Innovation Hub at the Matfors facility. This milestone marks a major step forward in NorthX’s commitment to the field of advanced therapies in Sweden, states NorthX. The Innovation Hub, co-funded by the Swedish Government, is poised to enhance the country’s infrastructure for cutting-edge therapies and accelerate […]
Biotech Business - August 29, 2023
Biovian invests over 50 million EUR in manufacturing facility
CDMO Biovian has announced a major investment to expand its manufacturing facility in Turku, Finland. The new facility will cover an area of 6,400 sqm and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies. It will […]
Acquisition - July 3, 2023
NorthX has acquired manufacturing unit from Valneva
NorthX Biologics has acquired the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden. The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University Hospital. In addition, 30 staff members who currently operate the facility will also join NorthX. “We are delighted to join forces with […]
CDMO - March 23, 2023
Biovian and Remedium collaborate on AAV gene therapy
The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L […]
CDMO - January 26, 2023
The critical role of Nordic CDMOs
Contract development and manufacturing organizations (CDMOs) are emerging as global key players within the pharmaceutical industry, and their Nordic presence and offering will give the region both resilience and a global competitive edge.
Acquisition - October 31, 2022
Curida acquires biologics manufacturer Diatec
Through the acquisition of Norwegian company Diatec, Curida takes the first steps into biological production. The acquisition strengthens the base on which Curida aims to grow further in the international CDMO market, it states. Before the acquisition, Curida provides manufacturing and development services out of two sites in Norway, and exports to more than 80 […]
